AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
bepridil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| vasodilators | 342 | 64706-54-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.30 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 5 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 18.20 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 61 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 10.10 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 14.90 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 28, 1990 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Interstitial lung disease | 98.46 | 38.10 | 34 | 366 | 78428 | 42542507 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Interstitial lung disease | 90.15 | 38.02 | 33 | 626 | 139301 | 110449339 |
| Cardiac tamponade | 50.36 | 38.02 | 12 | 647 | 11295 | 110577345 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C08EA02 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS NON-SELECTIVE CALCIUM CHANNEL BLOCKERS Phenylalkylamine derivatives |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:38215 | calcium channel blocker |
| MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002121 | Calcium Channel Blockers |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D014665 | Vasodilator Agents |
| MeSH PA | D049990 | Membrane Transport Modulators |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Angina pectoris | indication | 194828000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.79 | Basic |
| pKa2 | 3.96 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-dependent T-type calcium channel subunit alpha-1H | Ion channel | BLOCKER | Ki | 5.15 | WOMBAT-PK | CHEMBL | |||
| Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | BLOCKER | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Potassium channel subfamily K member 2 | Ion channel | IC50 | 5.39 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily KQT member 4 | Ion channel | BLOCKER | IC50 | 5 | IUPHAR | ||||
| Sodium channel protein type 5 subunit alpha | Ion channel | WOMBAT-PK | |||||||
| Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Ion channel | IC50 | 5.31 | WOMBAT-PK | |||||
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 6.08 | CHEMBL | |||||
| Potassium channel subfamily T member 1 | Ion channel | IC50 | 4.79 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.26 | WOMBAT-PK | |||||
| Voltage-dependent P/Q-type calcium channel subunit alpha-1A | Ion channel | BLOCKER | Ki | 6.60 | WOMBAT-PK | ||||
| Lethal factor | Enzyme | IC50 | 5.32 | CHEMBL | |||||
| Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | IC50 | 4.66 | CHEMBL | |||||
| Potassium channel subfamily T member 1 | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4019549 | VUID |
| N0000147653 | NUI |
| D00631 | KEGG_DRUG |
| 74764-40-2 | SECONDARY_CAS_RN |
| 1436 | RXNORM |
| C0005116 | UMLSCUI |
| CHEBI:3061 | CHEBI |
| BEP | PDB_CHEM_ID |
| CHEMBL1008 | ChEMBL_ID |
| CHEMBL1200382 | ChEMBL_ID |
| DB01244 | DRUGBANK_ID |
| D015764 | MESH_DESCRIPTOR_UI |
| 2351 | PUBCHEM_CID |
| 2337 | IUPHAR_LIGAND_ID |
| 3465 | INN_ID |
| 755BO701MA | UNII |
| 4267 | MMSL |
| d00688 | MMSL |
| 4019549 | VANDF |
| 4019631 | VANDF |
| 003562 | NDDF |
| 004519 | NDDF |
| 108530004 | SNOMEDCT_US |
| 108531000 | SNOMEDCT_US |
| 372503006 | SNOMEDCT_US |
Pharmaceutical products:
None